Huck constance

New IBCG consensus: Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group (IBCG) Full text: authors.elsevier.com/a/1mf5C_6tuO0S… @shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery

Using individual patient data we found strong evidence of benefit across endpoints: PFS, radiographic PFS (rPFS), and castration resistance free survival (CRFS). Overall survival (OS) barely missed significance with P=0.051 in the mixed effect model

Examining guidelines on radiotherapy for #BladderCancer with carcinoma in situ. @ConstanceHuck joins @UroDocAsh to examine whether carcinoma in situ should contraindicate trimodality therapy for muscle-invasive bladder cancer. The conversation highlights how historical data showing poor outcomes with CIS may be outdated, as older studies used split-course radiotherapy and inferior imaging techniques. #WatchNow on UroToday to learn more > bit.ly/4pVb8NA

"On ne ressent aucune douleur" : qu'est-ce que la #radiothérapie #stéréotaxique, cette méthode innovante qui soigne les #cancers masculins ? #CancerDeLaProstate @ConstanceHuck @Achard_Verane #CancerDeLaVessie #MedPhys #RadOncNews | #hcsmeufr @scoopit sco.lt/9GmoC0

Commented in EUO on RAMPP trial: • 💊 Limited modern systemic Tx • 🔍 Stage-migration with PSMA PET • ⏸️ Early stop → underpowered CSM signal • ⚠️ Higher morbidity vs RT ➡️ 🎯 RT remains the most evidence-based local option in oligometastatic HSPC.

Adjuvant radiotherapy evaluated for high-risk #BladderCancer after cystectomy. @VedangMurthy @TataMemorial joins @l_ballas @CedarsSinai presenting BART trial results, demonstrating adjuvant pelvic radiotherapy benefits for high-risk post-cystectomy bladder cancer patients. #WatchNow > bit.ly/4nnHFLb

🧪 Progress for bladder-sparing in MIBC: An international consensus standardizes clinical complete response (cCR) and endorses event-free survival (EFS) as the key endpoint for next-gen perioperative trials. #BladderCancer @JCO_ASCO ascopubs.org/doi/abs/10.120…

What the best approach for BCG-unresponsive NMIBC ? If you are worried about the expenses like Donald Trump or @MRoupret, think about Radiation Therapy like @Achard_Verane !! #focus2025

GU005 allowed hotspots of 38.7 Gy. PACE-B allowed hotspots of 48-50 Gy. So there is a 13 Gy eqd2 difference even between prescription doses and even more when accounting for hotspots. Thus GU005 had a bit more BCR but lower tox. PACE-B had a little better BCR and more tox. Just dose

💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo: 🔹 RT (n=77) vs Obs (n=76) 🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006) 🔹OS trend ↑RT (68% vs 57%), not sig 🔹No ↑ severe late adverse events 👉Adjuvant RT ↑ control & DFS, esp T3/4 & N+ pts. #ASTRO25 #RadOnc

#astro25 @NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT. Negative trial -OS no difference -PCSM no difference -DM no difference -BCR was not SS different with only 4% difference at 10 years. -toxicity increased 3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924. Goodbye WPRT

✨Our '' rising '' star, @ConstanceHuck discussing TMT in the context of CIS, with @UroDocAsh. 👂Listen this excellent discussion here @urotoday following the paper published in @EUplatinum urotoday.com/video-lectures…

📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4 full cycles Can we cure selected pts with MIBC with intravesical Rx + single agent IO? Future: is there a way to avoid #radicalcystectomy by consolidating Response with TAR200 in selected pts? Primary results with full biomarker results are awaited @Larvol @ASCO @myESMO @OncoAlert @urotoday @Medscape @SanRaffaeleMI @MyUniSR @JNJNews @spsutkaMD @DrFelixGuerrero @evanguelosx @BenjaminPradere #bladdercancer #clinicalresearch #MedTwitter #neoadjuvant thelancet.com/journals/lanon…

✍️🇫🇷 SFRO: FRENCH GUIDELINES FOR THE ROLE OF RADIOTHERAPY IN THE MANAGEMENT OF BLADDER CANCER @SFjROfr sciencedirect.com/science/articl…

🚨 MUST READ 🚨 🔥 Bladder preservation with CIS? Time to rethink the rules. 👉 New in EUO: sciencedirect.com/science/articl… 🙏 Grateful to the amazing team! #BladderCancer #Urology #RadiationTherapy #BladderPreservation #CIS

How to manage gynecomastia with ARPIs monotherapy? A review by @nassimVibert 🙏 sciencedirect.com/science/articl… #ProstateCancer #Prostate #life

@AinhoaMada @EORTC Thanks Ainhoa! Great team work !

@ConstanceHuck @EORTC Very well done Constance and team!

New insights on SBRT in recurrent ovarian cancer – now in CTRO: “SBRT in recurrent oligometastatic ovarian cancer: An EORTC Y-ECI GCG systematic review” 👉 doi.org/10.1016/j.ctro… 🎯 Local control ⏳ Delayed systemic therapy ⚖️ Personalized strategy @EORTC

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119) ⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy @drMPerera + team @Uroweb! ➡️link shorturl.at/unfn5

EAU Guidelines Update: European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines by Antoine G. van der Heijden et al Read the full update here: buff.ly/DFOK4dt #UroSoMe #MedTwitter #EurUrol #EAUGuidelines #GuidelinesUpdate